ATRC - AtriCure, Inc.
30.49 0.00 (0.00%)
After hours: 4:00PM EST
| Previous Close | 30.78 |
| Open | 30.68 |
| Bid | 30.53 x 800 |
| Ask | 30.58 x 2200 |
| Day's Range | 30.48 - 30.95 |
| 52 Week Range | 22.57 - 33.92 |
| Volume | 170,269 |
| Avg. Volume | 202,782 |
| Market Cap | 1.2B |
| Beta (5Y Monthly) | 0.30 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.61 |
| Earnings Date | Feb 26, 2020 - Mar 2, 2020 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 38.57 |
- American City Business Journals
Why AtriCure CEO Mike Carrel wants title of ‘heart surgeon’ for a day
Mike Carrel, CEO of AtriCure Inc., said the recent acquisition of a California firm that also makes devices to treat heart ailments could pay off not only for the Mason-based company and its shareholders but also for patients with atrial fibrillation.
- Insider Monkey
Did Hedge Funds Drop The Ball On AtriCure Inc. (ATRC) ?
Amid an overall bull market, many stocks that smart money investors were collectively bullish on surged through the end of November. Among them, Facebook and Microsoft ranked among the top 3 picks and these stocks gained 54% and 51% respectively. Our research shows that most of the stocks that smart money likes historically generate strong […]
- American City Business Journals
Medical device maker south of Dayton gets board refresh
One of the largest publicly traded companies in Miami Valley has named two new members to its board of directors.
- Business Wire
AtriCure Names Two Industry Veterans to Board of Directors
AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that Karen Prange and Daniel Florin have been named to its Board of Directors. Ms. Prange was most recently Executive Vice President and Chief Executive Officer for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein (HSIC) and a member of the Executive Committee.
- Simply Wall St.
Is AtriCure, Inc.'s (NASDAQ:ATRC) CEO Paid Enough Relative To Peers?
Mike Carrel has been the CEO of AtriCure, Inc. (NASDAQ:ATRC) since 2012. This report will, first, examine the CEO...
- Business Wire
AtriCure to Participate at the Piper Jaffray 31st Annual Healthcare Conference
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in the upcoming Piper Jaffray 31st Annual Healthcare Conference in New York City.
- Thomson Reuters StreetEvents
Edited Transcript of ATRC earnings conference call or presentation 30-Oct-19 8:30pm GMT
Q3 2019 AtriCure Inc Earnings Call
- Zacks
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
AtriCure (ATRC) delivered earnings and revenue surprises of -17.86% and 1.90%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
- Business Wire
AtriCure Reports Third Quarter 2019 Financial Results
MASON, Ohio-- -- Worldwide revenue of $56.6 million – an increase of 13.4% year over year U.S. revenue of $46.1 million – an increase of 16.0% year over year International revenue of $10.5 million – an increase of 3.1% year over year AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced third quarter 2019 financial results. ...
- Insider Monkey
Is AtriCure Inc. (ATRC) A Good Stock To Buy ?
It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]
- Zacks
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Business Wire
AtriCure to Participate in Upcoming Investor Conferences
AtriCure, Inc. , a leading innovator in surgical treatments for atrial fibrillation and left atrial appendage management, today announced that the company will be participating in upcoming investor conferences.
- Insider Monkey
This Hedge Fund Returns 22% Annually, Here Are Its Latest Picks
DAFNA Capital Management was founded in 1999 by Dr. Nathan Fischel, who is the fund’s CEO. Dr. Fischel is Pediatric Hematologist-Oncologist with a long career in medicine. He graduated from Technion School of Medicine in Israel and completed his residency at the Children’s Hospital and Dana-Farber Cancer Institute, Harvard Medical School, Boston. He continued his […]
- Simply Wall St.
Does AtriCure's (NASDAQ:ATRC) Share Price Gain of 64% Match Its Business Performance?
It hasn't been the best quarter for AtriCure, Inc. (NASDAQ:ATRC) shareholders, since the share price has fallen 20% in...
- Business Wire
AtriCure to Announce Third Quarter 2019 Financial Results
AtriCure, Inc. , a leading innovator in treatments for atrial fibrillation and left atrial appendage management, today announced that it will release its third quarter 2019 financial results on Wednesday, October 30, 2019.
- Simply Wall St.
How AtriCure, Inc.'s (NASDAQ:ATRC) Earnings Growth Stacks Up Against The Industry
When AtriCure, Inc. (NASDAQ:ATRC) released its most recent earnings update (30 June 2019), I compared it against two...
- Zacks
AtriCure Gains Expanded Labeling for Atriclip, Braces LAA Arm
AtriCure's (ATRC) AtriClip devices are currently the most widely implanted left atrial appendage management devices globally.
- Thomson Reuters StreetEvents
Edited Transcript of ATRC earnings conference call or presentation 30-Jul-19 8:30pm GMT
Q2 2019 AtriCure Inc Earnings Call
Motley FoolAtriCure Inc (ATRC) Q2 2019 Earnings Call Transcript
ATRC earnings call for the period ending June 30, 2019.
